Acurx Pharmaceuticals, Inc. ACXP

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum ("GPSS®") that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid ("DNA") polymerase IIIC ("pol IIIC"), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Our research and development ("R&D") pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile ("C. difficile"), methicillin-resistant Staphylococcus aureus ("MRSA"), vancomycin resistant Enterococcus ("VRE") and drug-resistant Streptococcus pneumoniae ("DRSP") and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).

Last close 1.14 2026-10-23
Market cap $6.0M 2026-06-30 share count
52-week range 1.07 - 7.54

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-5.32

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
R&D $1.8M$5.4M$6.0M$4.8M$2.0M$2.2M—
SG&A $6.3M$8.7M$8.5M$7.3M$10.8M$2.4M—
Total operating expenses $8.1M$14.1M$14.6M$12.1M$12.8M$4.6M—
Operating income -$8.1M-$14.1M—————
Pre-tax income ———-$12.1M—-$4.6M—
Income tax ———$0—$0—
Net income -$8.0M-$14.1M-$14.6M-$12.1M-$12.7M-$4.6M—
EPS, basic -5.32-17.45-1.15-1.12-1.49-0.74—
EPS, diluted -5.32-17.45-1.15-1.12-1.49-0.74—
Shares, diluted (wtd. avg.) 1.5M808,16812.7M10.8M8.5M6.2M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $7.6M$3.7M$7.5M$9.1M$13.0M$3.2M$2.5M
Total assets $7.7M$3.9M$7.7M$9.4M$13.3M$3.2M—
Accounts payable $2.4M$3.2M$3.0M$2.1M$843.9K$455.9K—
Total current liabilities $2.4M$3.2M$3.0M$2.1M$843.9K$472.6K—
Total liabilities $2.4M$3.2M$3.0M$2.1M$843.9K$522.4K—
Retained earnings -$75.3M-$67.3M-$53.2M-$38.6M-$26.5M-$13.8M—
Total equity $5.3M$615.1K$4.7M$7.3M$12.4M$2.7M—

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$6.8M-$10.4M-$9.8M-$7.5M-$5.0M-$3.4M—
Stock-based compensation $1.2M$2.6M$3.2M$2.9M$5.2M$695.8K—
Financing cash flow $10.6M$6.6M$8.2M$3.7M$14.8M$4.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-027052.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -15M -10M -5M 0 Net income, FY2020: -4.6M Net income, FY2021: -12.7M Net income, FY2022: -12.1M Net income, FY2023: -14.6M Net income, FY2024: -14.1M Net income, FY2025: -8M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — —
Gross profit — — — — — — —
Net income — -$4.6M -$12.7M -$12.1M -$14.6M -$14.1M -$8.0M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Charter or fiscal year changed Item 5.03
  • Other event Item 8.01
  • Shareholder vote Item 5.07

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%